

Institut Curie and Mirada Medical sign a collaboration agreement for the clinical use of DLCExpert™, Mirada's artificial intelligence (AI)-based autocontouring software for radiation therapy

Paris, France, and Oxford, UK, 16th April, 2018 – Mirada Medical, a leading global brand in medical imaging software, has signed a collaboration agreement with Institut Curie for the clinical use of DLCExpert™, Mirada's AI-based autocontouring software for radiation therapy.

Institut Curie, one of the largest oncology research centers in Europe, has been using Mirada's atlas-based autocontouring solutions for several years. Leading clinicians, who also co-author ESTRO (European Society for Radiotherapy and Oncology) contouring guidelines, recognize the potential clinical gains in using an AI-based solution for their contouring in radiotherapy. The agreement covers Institut Curie's adoption of Mirada's DLCExpert platform for radiation therapy, including training the deep learning model on its carefully curated patient data. This same model may subsequently be used in other hospitals and clinics.

"We are excited to be amongst the first institutions to use Mirada's groundbreaking technology. It will allow us to continue our pursuit of better treatments for our patients and to share our expertise with other centers around the world," says **Pr. Philip M.P. Poortmans, Head of Department of Radiation Oncology at Institut Curie.**

DLCExpert is Mirada's first AI-based clinical application. It automates most of the time-consuming clinical task of contouring organs-at-risk during radiation treatment planning. While other autocontouring solutions exist, they often require substantial contour editing. Automation using DLCExpert brings greatly improved contour accuracy and consistency which in turn considerably reduces the clinician's time spent editing.

Dr Mark Gooding, Chief Scientist at Mirada Medical said, *"The enthusiasm of the radiation oncologists at Institut Curie to share their contouring expertise using this technology is truly inspirational. For Mirada, DLCExpert has never been about the power of AI, but about improving patient care. Our partners at Institut Curie share our vision in this"*.

Matthieu Leclerc-Chalvet, Mirada's Managing Director for Europe adds, *"This agreement marks an important development in our relationship with Institut Curie. We're proud and excited to receive their vote of confidence in this new generation of deep learning-based autocontouring. This represents a key development for Institut Curie's state-of-the-art patient care, and we are looking forward to continuing our successful collaboration."*

"Institut Curie, the cradle of radiation therapy, has already been using Mirada imaging technology to bring efficiency gains across our three clinical sites through image fusion, adaptive radiation therapy, and molecular imaging. We are truly excited about this new partnership that will boost technology transfer in the AI field for radiation oncology analysis," concludes **Amaury Martin, Head of Institut Curie Technology Transfer and Industrial Partnerships Office and Director of the Institut Curie Cancer.**

About Mirada

Mirada is a leading international brand that develops software applications that simplify solutions to complex image analysis problems in the diagnosis and treatment of cancer. Through automation, our products improve consistency and productivity while enabling clinicians to deliver more personalized care. By combining deep learning technology with our thorough understanding of the challenges faced in oncology today, Mirada is leading the development of next generation imaging software and decision support products. Our staff are passionate about using their expertise to help our customers provide better healthcare for more patients.

To learn more about Mirada Medical, please visit: www.mirada-medical.com

About Institut Curie

Institut Curie, a key player in the fight against cancer, combines a leading French research center in oncology and a state-of-the-art hospital group that treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, Institut Curie

brings together more than 3,300 researchers, physicians and healthcare professionals around its three missions: care, research and teaching. As a private foundation recognized for public utility, Institut Curie is authorized to receive donations and bequests and can, thanks to the support of its donors, accelerate discoveries and thus improve the treatment and the quality of life of the patients.

For more information: <http://techtransfer.institut-curie.org/> <http://www.institut-curie.org>

Since 2011, Institut Curie is certified "Institut Carnot Curie Cancer". The Carnot label is a label of excellence granted to academic research structures with proven high quality and involvement in partnership research. Curie Cancer offers industrial partners the opportunity to set up research collaborations, benefiting from the expertise of the Institut Curie teams, for the development of innovative therapeutic solutions against cancers from the therapeutic target to clinical validation. For more information: <http://www.instituts-carnot.eu/fr/institut-carnot/curie-cancer>

Contacts:

Institut Curie / HOPSCOTCH : H  l  ne Bl  her : + 33 (0)1 41 34 18 65 hbleher@hopscotch.fr

Mirada Medical : Annamaria Albano, +44 1865 261 410 annamaria.albano@mirada-medical.com